Trial · NCT03401229
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Total NPS at Week 40 | Benra 30 mg | -0.36 | Standard Deviation 1.66 | Score on a scale | |
| Change From Baseline in Total NPS at Week 40 | Placebo | 0.17 | Standard Deviation 1.18 | Score on a scale | |
| Change From Baseline in NBS at Week 40 | Benra 30 mg | -0.68 | Standard Deviation 1.02 | Score on a scale | |
| Change From Baseline in NBS at Week 40 | Placebo | -0.41 | Standard Deviation 0.89 | Score on a scale | |
| Change From Baseline in SNOT-22 at Week 40 | Benra 30 mg | -15.2 | Standard Deviation 30.47 | Score on a scale | |
| Change From Baseline in SNOT-22 at Week 40 | Placebo | -10.7 | Standard Deviation 31.64 | Score on a scale | |
| Time to First NP Surgery and/or SCS Use for NP to Week 56 | Benra 30 mg | 35.5 | 95% Confidence Interval 29.3 to 42.5 | months | |
| Time to First NP Surgery and/or SCS Use for NP to Week 56 | Placebo | 46.5 | 95% Confidence Interval 39.7 to 53.8 | months | |
| Time to the First NP Surgery up to Week 56 | Benra 30 mg | 16.6 | 95% Confidence Interval 12.1 to 22.5 | months | |
| Time to the First NP Surgery up to Week 56 | Placebo | 19.5 | 95% Confidence Interval 14.5 to 25.9 | months | |
| Change From Baseline in DSS at Week 40 | Benra 30 mg | -0.34 | Standard Deviation 0.74 | Score on a scale | |
| Change From Baseline in DSS at Week 40 | Placebo | -0.16 | Standard Deviation 0.65 | Score on a scale | |
| Change From Baseline in NPS at Week 56 | Benra 30 mg | -0.22 | Standard Deviation 1.76 | Score on a scale | |
| Change From Baseline in NPS at Week 56 | Placebo | 0.18 | Standard Deviation 1.44 | Score on a scale | |
| Change From Baseline in NBS at Week 56 | Benra 30 mg | -0.68 | Standard Deviation 1.03 | Score on a scale | |
| Change From Baseline in NBS at Week 56 | Placebo | -0.38 | Standard Deviation 0.91 | Score on a scale | |
| Change From Baseline in SNOT-22 at Week 56 | Benra 30 mg | -15.1 | Standard Deviation 33.55 | Score on a scale | |
| Change From Baseline in SNOT-22 at Week 56 | Placebo | -7.9 | Standard Deviation 33.22 | Score on a scale | |
| Change From Baseline in DSS at Week 56 | Benra 30 mg | -0.39 | Standard Deviation 0.79 | Score on a scale | |
| Change From Baseline in DSS at Week 56 | Placebo | -0.21 | Standard Deviation 0.65 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03401229/results